Teaming up for CAR-T cell therapy.
作者信息
Wäsch Ralph, Munder Markus, Marks Reinhard
机构信息
Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg
Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz, Germany.
出版信息
Haematologica. 2019 Dec;104(12):2335-2336. doi: 10.3324/haematol.2019.228676.
Abstract
摘要
相似文献
1
Teaming up for CAR-T cell therapy.携手开展嵌合抗原受体T细胞（CAR-T）疗法。
Haematologica. 2019 Dec;104(12):2335-2336. doi: 10.3324/haematol.2019.228676.
2
[The Chinese consensus for the CAR-T cell therapy in multiple myeloma (2022 version)].《中国多发性骨髓瘤嵌合抗原受体T细胞疗法共识（2022年版）》
Zhonghua Xue Ye Xue Za Zhi. 2022 Apr 14;43(4):265-271. doi: 10.3760/cma.j.issn.0253-2727.2022.04.001.
3
[Chimeric antigen receptor T-cell therapy for multiple myeloma].嵌合抗原受体T细胞疗法治疗多发性骨髓瘤
Rinsho Ketsueki. 2018;59(10):2189-2194. doi: 10.11406/rinketsu.59.2189.
4
The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma.嵌合抗原受体T细胞疗法治疗多发性骨髓瘤的未来
Biol Blood Marrow Transplant. 2019 Mar;25(3):e73-e75. doi: 10.1016/j.bbmt.2018.11.009. Epub 2018 Nov 16.
5
Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment.嵌合抗原受体T细胞疗法在肾功能不全的复发/难治性多发性骨髓瘤中的安全性和有效性
Bone Marrow Transplant. 2020 Nov;55(11):2215-2218. doi: 10.1038/s41409-020-0930-5. Epub 2020 May 9.
6
CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma.CARTIFAN-1：关于嵌合抗原受体T细胞疗法在全球范围内用于多发性骨髓瘤的致命不良事件。
Eur J Cancer. 2023 Mar;182:1-2. doi: 10.1016/j.ejca.2022.12.018. Epub 2022 Dec 29.
7
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原免疫疗法对多发性骨髓瘤具有广阔的应用前景。
Ann Hematol. 2019 Apr;98(4):813-822. doi: 10.1007/s00277-018-03592-9. Epub 2019 Jan 28.
8
[Cell therapy's poster child: Chimeric antigen receptor T cell therapy].[细胞疗法的典型代表：嵌合抗原受体T细胞疗法]
Sheng Wu Gong Cheng Xue Bao. 2019 Dec 25;35(12):2339-2349. doi: 10.13345/j.cjb.190291.
9
Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma.关于CARTIFAN-1：全球范围内嵌合抗原受体T细胞疗法用于多发性骨髓瘤的致命不良事件
Eur J Cancer. 2023 Jul;188:108-110. doi: 10.1016/j.ejca.2023.04.003. Epub 2023 May 23.
10
Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions.嵌合抗原受体T细胞疗法治疗多发性骨髓瘤——挑战与潜在解决方案
JAMA Oncol. 2022 Jun 1;8(6):823-824. doi: 10.1001/jamaoncol.2022.0319.
引用本文的文献
1
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors.实体瘤嵌合抗原受体T细胞免疫疗法的进展与障碍
Cancers (Basel). 2022 Oct 18;14(20):5108. doi: 10.3390/cancers14205108.
2
Adverse Renal Effects of Anticancer Immunotherapy: A Review.抗癌免疫疗法的肾脏不良反应：综述
Cancers (Basel). 2022 Aug 23;14(17):4086. doi: 10.3390/cancers14174086.
3
Allogeneic Stem Cell Transplantation in Multiple Myeloma.多发性骨髓瘤中的异基因干细胞移植
Cancers (Basel). 2021 Dec 23;14(1):55. doi: 10.3390/cancers14010055.
4
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.考虑患者、疾病和治疗相关因素，为复发/难治性多发性骨髓瘤（RRMM）患者选择合适的治疗方法。
Cancers (Basel). 2021 Aug 26;13(17):4320. doi: 10.3390/cancers13174320.
5
Novel immunotherapies in multiple myeloma - chances and challenges.新型免疫疗法在多发性骨髓瘤中的应用——机遇与挑战。
Haematologica. 2021 Oct 1;106(10):2555-2565. doi: 10.3324/haematol.2020.266858.
6
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.欧洲骨髓瘤网络对 CAR T 细胞疗法治疗多发性骨髓瘤的看法。
Haematologica. 2021 Aug 1;106(8):2054-2065. doi: 10.3324/haematol.2020.276402.
本文引用的文献
1
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤：来自欧洲骨髓瘤网络的共识声明。
Haematologica. 2019 Dec;104(12):2358-2360. doi: 10.3324/haematol.2019.224204. Epub 2019 Aug 22.
2
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.抗 BCMA CAR T 细胞疗法 bb2121 治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.
3
Mechanisms of resistance to CAR T cell therapy.CAR T 细胞治疗耐药的机制。
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. doi: 10.1038/s41571-019-0184-6.
4
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
5
Are CAR T cells better than antibody or HCT therapy in B-ALL?嵌合抗原受体 T 细胞疗法（CAR-T 细胞疗法）是否优于抗体或造血干细胞移植（HCT）疗法治疗 B 细胞急性淋巴细胞白血病（B-ALL）？
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):16-24. doi: 10.1182/asheducation-2018.1.16.
6
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
7
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.同种异体移植多发性骨髓瘤患者可能允许在精心选择的患者中实现长期生存，这些患者具有可接受的毒性和保留的生活质量。
Haematologica. 2019 Feb;104(2):370-379. doi: 10.3324/haematol.2018.200881. Epub 2018 Sep 20.
8
Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome.外周血移植物用于 T 细胞充足的单倍体相合移植会增加细胞因子释放综合征的发生率和严重程度。
Biol Blood Marrow Transplant. 2018 Aug;24(8):1664-1670. doi: 10.1016/j.bbmt.2018.04.010. Epub 2018 Apr 19.
9
Current developments in immunotherapy in the treatment of multiple myeloma.多发性骨髓瘤治疗中免疫疗法的最新进展。
Cancer. 2018 May 15;124(10):2075-2085. doi: 10.1002/cncr.31243. Epub 2018 Feb 6.
10
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.急性淋巴细胞白血病中CD19嵌合抗原受体疗法的长期随访
N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.
Zotero 插件